Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
Background Preclinical and clinical data support potential synergy between anti-HER2 therapy plus immune checkpoint blockade. The safety and tolerability of trastuzumab emtansine (T-DM1) combined with pembrolizumab is unknown.Methods This was a single-arm phase Ib trial (registration date January 26...
Main Authors: | Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-10-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/10/10/e005119.full |
Similar Items
-
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
by: Tal Sella, et al.
Published: (2022-11-01) -
Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
by: Marion Lepelley, et al.
Published: (2018-11-01) -
Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
by: Laura M. Spring, et al.
Published: (2021-08-01) -
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
by: Tanya E. Keenan, et al.
Published: (2021-09-01) -
Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
by: Samy Hakroush, et al.
Published: (2021-11-01)